Insulet Corp. (NASDAQ:PODD) stock traded lower Wednesday after the insulin pump maker reported second-quarter results that topped Wall Street expectations but lowered its full-year revenue guidance and issued third-quarter sales guidance that came in below analysts’ estimates.

Adjusted earnings rose to $1.66 per share from $1.17 a year earlier, beating the analyst consensus estimate of $1.45. Revenue increased 23.5% year over year to $801.7 million, topping the Street estimate of $787.2 million.

Net income climbed to $95 million, or $1.37 per diluted share, from $22.5 million, or 32 cents per share, in the prior-year period.

Omnipod Sales Drive Strong Quarter

Total Omnipod revenue increased 24.6% to $795.9 million. U.S. Omnipod revenue rose 20.1% to $544.1 million, while international Omnipod revenue jumped 35.5% to $251.8 million. Drug Delivery revenue declined to $5.8 million from $10.2 million a year earlier.

Operating income increased to $129.7 million from $121.1 million, although the operating margin narrowed to 16.2% from 18.7%. Adjusted operating income rose to $154.5 million, representing 19.3% of revenue.

During the quarter, Insulet expanded Omnipod 5 into Spain, making it available in its 20th country, launched a next-generation algorithm for its automated insulin delivery system, and presented new data supporting its Omnipod 6 and fully closed-loop technology pipeline at the American Diabetes Association’s 2026 Scientific Sessions.

“We delivered another quarter of broad-based growth, robust margin expansion, and positive free cash flow,” CEO Ashley McEvoy said. She added that while the company is updating its outlook based on what it is learning as it expands in the Type 2 diabetes market, its long-term growth opportunity remains unchanged.

Insulet ended the second quarter with $534.9 million in cash and cash equivalents, down from $716.1 million at the end of 2025. The company generated $202.2 million in operating cash flow during the first six months of 2026 and reported free cash flow of $145.4 million.

Insulet Revenue Guidance Cut

For the third quarter, Insulet expects revenue of approximately $829.9 million to $844.0 million, below the analyst consensus estimate of $845.5 million.

The company also lowered its full-year 2026 revenue outlook to a range of approximately $3.25 billion to $3.30 billion from its prior forecast of $3.28 billion to $3.33 billion. The revised guidance also came in below the Wall Street estimate of $3.32 billion.

For 2026, Insulet expects adjusted EPS to exceed $6.46, above the analyst consensus estimate of $6.43.

Insulet Price Action

PODD Stock Price Activity: Insulet shares were down 12.13% at $146.58 during premarket trading on Wednesday, according to Benzinga Pro data.

Photo courtesy of Insulet